drugset / Trial / NCT00091650

Olanzapine in Patients With Borderline Personality Disorder

NCT00091650

Phase 3 Completed 300 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The goals of this study are to determine: the safety of olanzapine and any side effects that might be associated with it, how olanzapine compares to placebo, whether olanzapine can help patients with symptoms of Borderline Personality Disorder (BPD), and how much olanzapine should be given to patients.

Timeline

Start
2004-03
Primary completion
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule